FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:26:49.718Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T14:26:49.718Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:26:49.718Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:26:49.718Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T14:26:49.718Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:26:49.718Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:26:49.718Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands.
Medical - Instruments & Supplies · San Clemente, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
Product / business disclosures (FY 2025)
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Equipment revenue$74.84M
Software revenue$31.37M
Other deferred revenue$1.18M
Government Grant Revenue-$2.07M
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Reviewed labels link to their filing; other labels are unverified FMP source labels.
UNITED STATES$1.36B
EMEA$411.68M
Asia Pacific$232.90M
Other foreign countries$230.56M
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$547.88M
vs Estimate
$533.44M
Beat
ICUI Analyst Ratings
Consensus Rating
N/A
No analyst recommendations available
Strong Buy
0
Buy
0
Hold
0
Sell
0
Strong Sell
0
Average Price Target
N/A
Low
N/A
Current
$158.16
High
N/A
ICUI Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
Period
Low
Avg
High
# Analysts
Quarter ending Sep 2026
$2.12
$2.14
$2.16
5
Quarter ending Dec 2026
$2.16
$2.22
$2.27
5
Quarter ending Mar 2027
$2.11
$2.15
$2.18
3
Quarter ending Jun 2027
$2.33
$2.37
$2.40
3
Annual
Period
Low
Avg
High
# Analysts
FY 2026
$8.70
$8.74
$8.80
6
FY 2027
$9.45
$9.67
$10.05
6
Revenue Estimates
Quarterly
Period
Low
Avg
High
# Analysts
Quarter ending Sep 2026
$549.78M
$552.13M
$557.77M
6
Quarter ending Dec 2026
$552.14M
$561.03M
$565.55M
6
Quarter ending Mar 2027
$540.22M
$547.87M
$553.89M
3
Quarter ending Jun 2027
$559.51M
$567.43M
$573.67M
3
Annual
Period
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
